GEA Group AG

Regulatory Filings • Aug 19, 2009

News Details

Corporate | 19 August 2009 12:22

GEA Group Aktiengesellschaft: GEA wins major pharmaceutical order for EUR 15m from China

GEA Group Aktiengesellschaft / Miscellaneous

Announcement, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Bochum, August 19, 2009 - GEA has won a milestone order from the Zheiiang
Hisun Pharmaceutical Co. Ltd. in Taizhou Zheiiang, China for the supply of
pharmaceutical freeze dryers with automatic load and unload systems (ALUS).
The order is a major breakthrough in the region allowing Hisun to expand
its operations into formulated pharmaceutical products for injection focus
in oncology and infective diseases. The Pharma Systems Division, which
belongs to the Process Technology Segment of GEA Group, will supply seven
freeze drying systems and five ALUS systems with a total value in excess of
EUR 15 million. The equipment will be used at the new facilities in the
Fuyang pharmaceutical valley and will allow Hisun to focus on the
production of anti-tumour, anti-infective, general biologics and
anti-tuberculosis product for both the domestic and export markets. Hisun
is planning to invest over EUR 100 million in the Fuyang facility making it
one of the biggest pharmaceutical production sites in China.

'GEA is the technology leader for pharmaceutical freeze drying and
automatic load and unload systems. This new order will help sustain our
leading role in China in the future,' commented Niels Graugaard, member of
the Executive Board of GEA Group Aktiengesellschaft. 'We won this Hisun
contract because of our technical excellence, reputation for operational
reliability and proven capability of running large engineering projects for
the pharmaceutical industry. GEA Pharma Systems already holds an
established position in China with a major manufacturing facility in
Shanghai and an engineering, service and after-sales structure throughout
the country.'

Hisun has been a leading pharmaceutical manufacturer in China for over 50
years specialising in the production of active pharmaceutical ingredients
(APIs) for antibiotics and oncology products. Its products include
anti-infection, anti-parasite, endocrine regulation, immunosuppressant and
antidepressant drugs. The company is one of the biggest players in China:
home to one of the world's fastest-growing pharmaceutical industries. Hisun
exports more than 80 percent of its products and holds a leading market
position in over 30 countries in the Far East, Europe and the USA.

GEA Group Aktiengesellschaft is one of the largest pure mechanical
engineering groups in Germany. As an internationally operating technology
group, it concentrates on specialty mechanical engineering with a focus on
process technology and components. Group revenue amounted to EUR 5.2
billion in fiscal year 2008. The Group generated about 50 percent of its
revenue from the long-term growing food and beverage industries. As of June
30, 2009, a workforce of over 20,000 employees served customers in 50
countries. GEA Group is a market and technology leader in 90 percent of its
business areas. GEA Group is listed in the MDAX index (G1A, WKN 660200).
19.08.2009 Financial News transmitted by DGAP

---

Language: English
Issuer: GEA Group Aktiengesellschaft
Dorstener Straße 484
44809 Bochum
Deutschland
Phone: +49 (0)234 980-0
Fax: +49 (0)234 980-1004
E-mail: investor.relations@geagroup.com
Internet: www.geagroup.com
ISIN: DE0006602006
WKN: 660200
Indices: MDAX
Listed: Regulierter Markt in Berlin, Frankfurt (Prime Standard),
Düsseldorf, München, Hamburg; Freiverkehr in Hannover,
Stuttgart

End of News DGAP News-Service

---